Clinical trials: Myeloid Chimerism
Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
This clinical trial studies fludarabine phosphate, low-dose total-body irradiation, and donor stem cell transplant followed by cyclosporine, mycophenolate mofetil, and donor lymphocyte infusion in treating patients with…
- Conditions
- Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00006251
- Testing
- total-body irradiation, fludarabine phosphate, cyclosporine
- Where
- 2 sites in United States, Italy
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
This phase I trial studies the side effects and best dose of iodine I 131 monoclonal antibody BC8 when given together with fludarabine phosphate and low-dose total-body irradiation followed by donor stem cell transplant and…
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT00008177
- Testing
- iodine I 131 monoclonal antibody BC8, total-body irradiation, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Malignancies, Bone Marrow Transplant Rejection
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor's T cells (a type of lymphocyte, or white blood cell) are removed and then added back.
- Trial name
- NCT00079391
- Testing
- allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
AML, ALL
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
The purpose of this study is to provide allogeneic stem cell transplantation to patients who have not traditionally undergone this procedure because of it high incidence of treatment related side effects.
- Conditions
- AML, ALL, CML Chronic Phase, Accelerated Phase, or Blast Crisis, CLL
- Trial name
- MINI HEME (NCT00636909)
- Testing
- Cyclophosphamide, fludarabine, cyclosporine
- Volunteers
- 25 people
- Sponsor
- Beth Israel Deaconess Medical Center
Stem Cell Transplantation, Leukemia
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
The goal of this clinical research study is to learn if Vidaza (azacitidine) when given to patients with CML after an donor stem cell transplant will increase the likelihood of achieving a complete remission of CML.
- Trial name
- NCT00813124
- Testing
- Fludarabine, Busulfan, Thymoglobulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloid Malignancy
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor…
- Trial name
- NCT03850418
- Testing
- azacitidine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Henry Ford Health System
Leukemia
Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by radiation therapy used to kill tumor cells.
- Trial name
- NCT00005801
- Testing
- therapeutic allogeneic lymphocytes, peripheral blood stem cell transplantation, radiation therapy
- Where
- 2 sites in United States
- Sponsor
- University of Colorado, Denver
Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia
This clinical trial studies fludarabine phosphate, low-dose total-body irradiation, and peripheral blood stem cell transplant followed by donor lymphocyte infusion in treating older patients with chronic myeloid leukemia.
- Conditions
- Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease
- Trial name
- NCT00003145
- Testing
- Fludarabine Phosphate, Total-Body Irradiation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy.
- Trial name
- NCT00053014
- Testing
- therapeutic allogeneic lymphocytes, cyclosporine, fludarabine
- Where
- 83 sites in United States
- Volunteers
- 5 people
- Sponsor
- SWOG Cancer Research Network
Sickle Cell Anemia, Beta Thalassemia
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
Background: Sickle cell disease (SCD) is an inherited disorder of the blood. It can damage a person s organs and cause serious illness and death. A blood stem cell transplant is the only potential cure for SCD.
- Trial name
- NCT05357482
- Testing
- TBI, Hydroxyurea, briquilimab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia
Experimental Bone Marrow Transplant Protocol
Bone marrow transplantation (BMT) is a risky procedure. If doctors could reduce the complications, BMT would be safer to use for a wider range of conditions.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myelocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00061581
- Testing
- Isolex 300i Stem Cell Selection
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome)
Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
AlloHeme is a blood-based monitoring test developed by the CareDx laboratory that utilizes NGS technology coupled with a proprietary algorithm to predict the likelihood of a relapse in post-allo-HCT AML/MDS patients.
- Conditions
- AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), CMML
- Trial name
- FORWARD (NCT07607327)
- Testing
- AlloHeme
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- CareDx
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00096161
- Testing
- Cyclosporine, Mycophenolate Mofetil, Pentostatin
- Where
- 5 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Leukemia, Acute Myeloid Leukemia
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
There is no curative therapy once acute leukemia patients relapse after transplant. Patients who develop clinically significant graft versus host disease (GVHD) have a lower rate of relapse than those who do not develop GVHD.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Leukemia
- Trial name
- NCT01036009
- Testing
- Withdrawal of immunosuppression and donor lymphocyte infusion
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco
Myeloid Chimerism
Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
Background: Sickle cell disease can often be treated with blood stem cell transplants. But for some people the disease returns. This study will give a second transplant to people whose disease has returned but still have some…
- Trial name
- NCT04008368
- Testing
- CliniMACS CD34 Reagent
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
AlloHeme is a chimerism test service that utilizes NGS technology to analyze SNP loci to quantify donor and recipient cells by measuring genomic DNA.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- ACROBAT (NCT04635384)
- Where
- 10 sites in United States
- Volunteers
- 307 people
- Sponsor
- CareDx
Granulomatous Disease, Chronic
Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant
This protocol is designed for a single specific patient. It uses busulfan as a conditioning agent in a second stem cell transplant procedure for a patient with chronic granulomatous disease (CGD), a disorder in which a certain…
- Trial name
- NCT00092937
- Testing
- Busulfan
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Myeloid Leukemia
Mismatched Donor Cells to Treat Acute Myeloid Leukemia
The purpose of this study is to assess the safety and efficacy of infusing immune cells from a donor as treatment for patients with acute myeloid leukemia that is resistant to chemotherapy or who have experienced relapse.
- Trial name
- ATAC-AML-01 (NCT01793025)
- Testing
- ATAC Therapy
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Leukemia, Myeloid, Myelodysplastic Syndromes
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
The purpose of this study is to determine the maximum tolerated dose, dose limiting side effects, and the safety of increasing doses of lenalidomide in patients with AML and MDS who have a small amount of detectable disease after…
- Trial name
- UF-BMT-MRD-101 (NCT02370888)
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Florida